Reuters logo
BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib
November 17, 2017 / 12:20 PM / a month ago

BRIEF-Agios presents updated phase 1 data from dose expansion cohort of ivosidenib

Nov 17 (Reuters) - Agios Pharmaceuticals Inc

* Agios presents updated phase 1 data from dose expansion cohort of ivosidenib (AG-120) in patients with IDH1 mutant positive glioma

* Agios Pharmaceuticals Inc - ‍ivosidenib well-tolerated in patients with low grade glioma​

* Agios Pharmaceuticals Inc - ‍additional preclinical data demonstrate that ivosidenib and AG-881 suppress 2-HG levels in brain tumor mouse models​

* Agios Pharmaceuticals Inc - ‍there were 5 patients with serious adverse events (SAE) and all were deemed unrelated to study treatment​

* Agios Pharmaceuticals - ‍preliminary data suggest that both molecules suppress oncometabolite D-2-hydroxyglutarate in an orthotopic brain tumor model​

* Agios Pharmaceuticals - study ‍to refine imaging methodology, assess biological effects of IDH inhibitors in perioperative study planned for H1 of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below